Outsourcing Drivers By Company Size
Source: ISR Reports
In Q4 2018, ISR surveyed 121 outsourcers of large molecule drug substance manufacturing to understand their primary reason for working with CMOs for biologic API. The data show respondents from small companies, with an annual R&D spend under $1B, are more likely to use CMOs for all of their manufacturing needs than respondents from large pharma companies (61% vs 24%). Conversely, respondents from large pharma companies are more likely to use CMOs to augment their internal manufacturing capacity (57% vs 31%) and to access additional markets (15% vs 2%).
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more